Ultragenyx to Participate in Investor Conferences in December

RARE 11.26.2024

Full Press ReleaseSEC FilingsOur RARE Tweets

About Gravity Analytica

Recent News

  • 01.17.2025 - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  • 01.13.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.12.2025 - Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones

Recent Filings

  • 01.13.2025 - 8-K Current report
  • 01.13.2025 - EX-99.1 EX-99.1

NOVATO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced participation in three upcoming investor conferences.

Citi’s 2024 Global Healthcare Conference (Miami, FL)

  • Tuesday, December 3, 2024, Emil Kakkis, M.D., Ph.D., CEO and President and Howard Horn, Chief Financial Officer, will participate in a fireside chat and host 1x1 meetings.

7thAnnual Evercore ISI HealthCONx Conference (Coral Gables, FL)

  • Wednesday, December 4, 2024, Emil Kakkis and Howard Horn will participate in a fireside chat and host 1x1 meetings.

Piper Sandler’s 36thAnnual Healthcare Conference (New York, NY)

  • Thursday, December 5, 2024, Eric Crombez, M.D., Chief Medical Officer and Howard Horn will participate in a fireside chat and host 1x1 meetings.

The live and archived webcast of the fireside chats will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contacts – Ultragenyx Pharmaceutical, Inc.

InvestorsJoshua Higair@ultragenyx.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com